Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Shire to present at the 36th Annual J.P. Morgan Healthcare Conference
Cambridge, MA - January 4, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, M.D., M.P.H., Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in in San Francisco, California on Monday, January 8th, 2018, at 10:30 AM Pacific Standard Time (18:30 GMT).
A live audio webcast of the presentation and the questions & answers session will be available on Shire's Investor website at http://investors.shire.com/presentations-and-reports. Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | [email protected] | +41 79 543 3259 |
| Sun Kim | [email protected] | +1 617 588 8175 |
| Robert Coates | [email protected] | +44 203 549 0874 |
| Media | ||
| Lisa Adler | [email protected] | +1 617 588 8607 |
| Katie Joyce | [email protected] | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people's lives with medicines that have a meaningful impact on patients and all who support them on their journey.
